No Data
No Data
Gilead, GSK Could Be Impacted by Potential HHS HIV Prevention Cuts
Trump Administration Follows Biden in Defending 340B Drug-discount Program
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
Green Gives Way to Red on Gossamer Macro Expectations: Live Stock News
SA Charts: How Are M&A Deals Shaping up at the Start of 2025?
Johnson & Johnson (JNJ.US) has initiated a phase three clinical trial for an oral cyclic peptide targeting IL-23R for psoriatic arthritis.
The third phase clinical trial plans to enroll 540 patients with Silver psoriasis arthritis, expected to be completed preliminarily by 2026.